https://www.newhampshirehealthreport.com/article/905695842-major-shareholder-announcement New Hampshire Health Report en PressRelease 2026-04-14T14:44:22+00:00 Major Shareholder Announcement https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905697702-advanced-radiation-centers-of-new-york-launches-softray-therapy-offering-new-non-surgical-relief-of-inflammatory-tendon-and-arthritis-pain New Hampshire Health Report en PressRelease 2026-04-14T14:04:00+00:00 Advanced Radiation Centers of New York Launches SoftRay™ Therapy, Offering New Non-Surgical Relief of Inflammatory, Tendon and Arthritis Pain https://ml.globenewswire.com/media/de310bc0-7bc1-48f5-b455-ca8f8ffd0472/medium/softray-therapy-logo.png https://www.newhampshirehealthreport.com/article/905695461-zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations New Hampshire Health Report en PressRelease 2026-04-14T14:00:00+00:00 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations https://ml-eu.globenewswire.com/media/b505bacc-6953-4eb4-ab25-e03008f97b92/medium/eric-rojas.jpg https://www.newhampshirehealthreport.com/article/905696037-award-winning-medical-alert-system-bay-alarm-medical-launches-caregiver-sos-youtube-series-to-support-family-caregivers New Hampshire Health Report en PressRelease 2026-04-14T14:00:00+00:00 Award-winning Medical Alert System Bay Alarm Medical Launches 'Caregiver SOS' YouTube Series to Support Family Caregivers https://pressranger.s3.us-west-1.amazonaws.com/3140430/Screenshot-2026-03-06-at-12.32.15%E2%80%AFPM.png https://www.newhampshirehealthreport.com/article/905696490-neion-bio-strengthens-genome-engineering-leadership-with-appointment-of-colossal-biosciences-veteran-james-kehler New Hampshire Health Report en PressRelease 2026-04-14T14:00:00+00:00 Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James Kehler https://ml.globenewswire.com/media/e37518bc-d9ef-45ce-99a7-35e82f143444/medium/dr-james-kehler.jpg https://www.newhampshirehealthreport.com/article/905696688-reducing-administrative-burden-raises-medicaid-provider-satisfaction-by-50-new-study-finds New Hampshire Health Report en PressRelease 2026-04-14T14:00:00+00:00 Reducing Administrative Burden Raises Medicaid Provider Satisfaction by 50%, New Study Finds https://ml.globenewswire.com/media/24cdff2f-7c95-4f21-aebb-25c4628d94e7/small/gainwell-logo-suite-061720-logosuite-png-gainwell-logo-150-r.png https://www.newhampshirehealthreport.com/article/905697695-hibercell-to-present-preclinical-data-demonstrating-the-enhanced-antitumor-activity-of-hc-7366-in-combination-with-vegfr-tkis-in-clear-cell-renal-cell New Hampshire Health Report en PressRelease 2026-04-14T14:00:00+00:00 HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) https://ml.globenewswire.com/media/d168805a-8691-40f2-abcf-fb63a607f112/small/hybercell-jpg.jpg https://www.newhampshirehealthreport.com/article/905697837-grand-river-aseptic-manufacturing-announces-100-million-investment-in-sterile-manufacturing-capabilities New Hampshire Health Report en PressRelease 2026-04-14T13:55:44+00:00 Grand River Aseptic Manufacturing Announces $100 Million Investment in Sterile Manufacturing Capabilities https://ml.globenewswire.com/media/OTBkMmRlZDktNGMxYi00Mjk1LWE0YWMtZTBhYjhlOTMyMTFhLTUwMDE1MTE4Ny0yMDI2LTA0LTE0LWVu/tiny/Grand-River-Aseptic-Manufactur.png https://www.newhampshirehealthreport.com/article/905686836-culture-biosciences-announces-strategic-addition-to-its-board-of-directors-to-accelerate-hardware-commercialization-and-saas-growth New Hampshire Health Report en PressRelease 2026-04-14T13:30:00+00:00 Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth https://ml.globenewswire.com/media/ce8c1148-eecd-40b0-b1b7-f858ab8c3c4f/small/culture-logo-one-color-rgb-1500px-300ppi-1-1-png.png https://www.newhampshirehealthreport.com/article/905685691-virtuix-delivers-omni-one-to-florida-gulf-coast-university-for-use-in-physical-therapy-and-clinical-simulation New Hampshire Health Report en PressRelease 2026-04-14T13:15:00+00:00 Virtuix Delivers Omni One to Florida Gulf Coast University for Use in Physical Therapy and Clinical Simulation https://ml.globenewswire.com/media/2ba7d28b-48bc-45db-b49e-929295456dc1/medium/omni-one-at-fgu-s-marieb-college-of-health-and-human-service.jpeg https://www.newhampshirehealthreport.com/article/905685932-myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan New Hampshire Health Report en PressRelease 2026-04-14T13:15:00+00:00 Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan https://ml.globenewswire.com/media/5cb679cf-5a10-4b95-8cf7-fd1d0b56721a/small/myriad-s-stacked-png.png https://www.newhampshirehealthreport.com/article/905685481-nextech-reduces-healthcare-s-payment-reconciliation-burden-with-reimagined-embedded-payment-processing-platform New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 Nextech Reduces Healthcare’s Payment Reconciliation Burden with Reimagined Embedded Payment Processing Platform https://ml.globenewswire.com/media/2b32c79b-9e9d-48d1-ae49-77d47537ae62/small/nextech-logo-jpg-jpg.jpg https://www.newhampshirehealthreport.com/article/905685781-alliance-direct-benefits-launches-alliance-complete-as-demand-grows-for-simplified-bundled-support-offerings New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 Alliance Direct Benefits Launches Alliance Complete as Demand Grows for Simplified, Bundled Support Offerings https://ml.globenewswire.com/media/ZGM1MDA4YTEtODYzZi00YzgzLThkODAtMjEwNWJhZjU2NjQ2LTUwMDE2MDEwNC0yMDI2LTA0LTE0LWVu/tiny/Alliance-Direct-Benefits.png https://www.newhampshirehealthreport.com/article/905686904-healthedge-partners-with-ellipsis-health-to-scale-care-management-through-ai-powered-virtual-nursing New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 HealthEdge® Partners with Ellipsis Health to Scale Care Management Through AI-Powered Virtual Nursing https://ml.globenewswire.com/media/18d2dfaf-8f95-4f15-99e6-ae8282b42123/small/healthedge-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905686993-neomorph-to-highlight-progress-in-targeted-protein-degradation-science-at-the-american-association-for-cancer-research-annual-meeting New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905687330-haystack-health-appoints-digital-health-leader-bill-snyder-as-chief-executive-officer New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 Haystack Health Appoints Digital Health Leader Bill Snyder as Chief Executive Officer https://ml.globenewswire.com/media/f6629b37-d06b-4203-a6cd-f233134c4f32/small/hh-logo-png.png https://www.newhampshirehealthreport.com/article/905687785-merakris-therapeutics-and-ifyber-collaboration-receives-top-sawc-research-award-for-mtx-001-wound-healing-study-in-human-skin-model New Hampshire Health Report en PressRelease 2026-04-14T13:00:00+00:00 Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png https://www.newhampshirehealthreport.com/article/905685907-just-salad-opens-in-east-amherst-n-y New Hampshire Health Report en PressRelease 2026-04-14T12:57:00+00:00 Just Salad Opens in East Amherst, N.Y. https://ml.globenewswire.com/media/0bfa206d-0a40-4b13-a05a-267ebef25a6a/medium/just-salad-east-amherst-new-york-storefront.jpg https://www.newhampshirehealthreport.com/article/905688308-entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-treatment-landscape-and-the-opportunity-for-eb613 New Hampshire Health Report en PressRelease 2026-04-14T12:45:00+00:00 Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 https://ml.globenewswire.com/media/9b4ae2bf-733d-4180-b48c-d0fa3f26c81a/small/logo-png.png https://www.newhampshirehealthreport.com/article/905688406-actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus New Hampshire Health Report en PressRelease 2026-04-14T12:45:00+00:00 Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma https://ml.globenewswire.com/media/f65ca94c-eff8-4376-ac67-ded1b03b3bcc/small/actuatetx-logo-color300-jpg.jpg https://www.newhampshirehealthreport.com/article/905688494-extendicare-announces-closing-of-450-million-inaugural-offering-of-investment-grade-senior-unsecured-notes New Hampshire Health Report en PressRelease 2026-04-14T12:39:06+00:00 Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://www.newhampshirehealthreport.com/article/905686858-cellectar-enrolls-first-patient-in-clr-125-auger-emitting-radioconjugate-phase-1b-clinical-trial-targeting-refractory-triple-negative-breast-cancer New Hampshire Health Report en PressRelease 2026-04-14T12:35:00+00:00 Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.newhampshirehealthreport.com/article/905686003-pelthos-therapeutics-to-participate-in-piper-sandler-spring-biopharma-symposium New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium https://ml.globenewswire.com/media/7d71f2d0-a48f-4fe0-a49c-138de21bc0e1/small/pelthos-logo-rgb-png.png https://www.newhampshirehealthreport.com/article/905686896-cytodyn-to-present-at-the-aacr-annual-meeting-2026 New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 CytoDyn to Present at the AACR Annual Meeting 2026 https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://www.newhampshirehealthreport.com/article/905687404-clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorx-s-tamp-therapy-platform-presented-at-2026-sir-annual-scientific-meeting New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://www.newhampshirehealthreport.com/article/905688178-join-nexalin-s-exclusive-live-investor-webinar-and-q-a-session-on-april-21 New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 https://ml.globenewswire.com/media/7f481b55-16b6-4c8a-8356-30d54079a605/small/nexalin-jpg.jpg https://www.newhampshirehealthreport.com/article/905688250-meiragtx-to-present-3-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-radiation-induced-xerostomia-on New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 https://ml.globenewswire.com/media/6b45b8d0-975e-494b-8a46-b88360aa1791/small/mgx-logo-png.png https://www.newhampshirehealthreport.com/article/905688290-tomi-reports-strong-q1-2026-sales-of-high-margin-bit-solution-indicating-positive-growth-trends New Hampshire Health Report en PressRelease 2026-04-14T12:30:00+00:00 TOMI Reports Strong Q1 2026 Sales of High-Margin BIT Solution, Indicating Positive Growth Trends https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.newhampshirehealthreport.com/article/905687539-biomerica-launches-infoods-ibs-in-canada-through-partnerships-with-phoenix-airmid-biomedical-and-canalt-health-labs New Hampshire Health Report en PressRelease 2026-04-14T12:19:00+00:00 Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://www.newhampshirehealthreport.com/article/905673841-inspira-technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-growth-and-quantum-expansion New Hampshire Health Report en PressRelease 2026-04-14T12:01:00+00:00 Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.newhampshirehealthreport.com/article/905669423-community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-charitable-clinics New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.newhampshirehealthreport.com/article/905669681-amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-u-s New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.newhampshirehealthreport.com/article/905669769-biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/f437d04b-c089-46eb-bca8-7ef64f68bc9b/small/biovie-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905669779-grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 https://ml.globenewswire.com/media/c71c0a95-caed-4520-87a9-ac7fefef3f07/small/grce-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905670492-er-kim-signs-exclusive-distribution-agreement-with-leo-pharma-a-s-to-commercialize-loqtorzi-toripalimab-for-nasopharyngeal-and-oesophageal-cancers New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers https://ml.globenewswire.com/media/37d25207-4dc0-4c58-b0cc-d589d363d644/small/erkim-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905670506-hinge-bio-announces-first-subject-dosed-in-phase-1-trial-of-hb2198-a-novel-b-cell-depleting-agent-for-treating-autoimmune-disease New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease https://ml.globenewswire.com/media/62e1a1c6-154c-4dec-bfb4-79d43b015626/small/hinge-logo-color-2021-jpg.jpg https://www.newhampshirehealthreport.com/article/905671256-genecentric-to-present-data-on-fragmentomics-based-expressct-liquid-biopsy-technology-at-aacr-2026 New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 https://ml.globenewswire.com/media/90d634f2-8dea-4f53-805f-e1e0eaa71133/small/genecentric-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905671300-rivus-pharmaceuticals-announces-first-patients-dosed-in-amplify-phase-2-trial-for-hu6-in-mash New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH https://ml.globenewswire.com/media/b85bbdee-9fda-4cf2-a14f-d2d608f0b949/small/rivus-pharmaceuticals-logo-png.png https://www.newhampshirehealthreport.com/article/905671534-carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026 New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://www.newhampshirehealthreport.com/article/905671584-nanox-announces-collaboration-with-meir-medical-center-to-deploy-nanox-arc-for-orthopedic-imaging-clinical-study New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.newhampshirehealthreport.com/article/905672627-corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905672678-tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts https://ml.globenewswire.com/media/6ddb04fb-e5ac-416b-b90b-b4cbf51dc538/small/blue-logo-stacked-jpg.jpg https://www.newhampshirehealthreport.com/article/905672686-genvor-announces-strategic-memorandum-of-understanding-with-canlab-international-to-advance-commercial-peptide-pipeline New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline https://ml.globenewswire.com/media/8533fef9-aa8f-43c5-9088-39ab06147641/small/43464-png.png https://www.newhampshirehealthreport.com/article/905672832-real-world-evidence-and-industry-momentum-builds-for-imdx-s-flagship-graftassure-assay New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay https://ml.globenewswire.com/media/418fe8d1-a6a4-4025-84ba-56f14ee83865/small/imdx-logo-png.png https://www.newhampshirehealthreport.com/article/905673675-calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjav-k-iceland-on-april-28th-highlighting-the-redtail-platform-s New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.newhampshirehealthreport.com/article/905674131-aclarion-receives-pinnacle-award-for-ai-innovation New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Aclarion Receives Pinnacle Award for AI Innovation https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.newhampshirehealthreport.com/article/905674226-r1-announces-revenue-performance-solutions-powered-by-phare-os-to-help-providers-navigate-growing-complexity-and-margin-pressure New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://www.newhampshirehealthreport.com/article/905674385-prenetics-im8-health-partners-with-vitamin-angels-to-combat-global-malnutrition-commits-to-impacting-400-000-mothers-and-children-in-year-one New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One https://ml.globenewswire.com/media/106dbe1a-a6e1-49d9-97a2-c5609258bdc7/small/pre-logo-2026-png.png https://www.newhampshirehealthreport.com/article/905674450-clairity-announces-update-to-nccn-guidelines-to-include-ai-mammogram-based-risk-tool-to-identify-future-breast-cancer-risk-in-women-missed-by New Hampshire Health Report en PressRelease 2026-04-14T12:00:00+00:00 Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods https://ml.globenewswire.com/media/0087b812-cef6-4183-8b7c-093385f3bcb5/small/clairitylogo-fullcolor-vertical-rgb-png.png https://www.newhampshirehealthreport.com/article/905671949-avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrating-accelerated-time-to-skin-grafting New Hampshire Health Report en PressRelease 2026-04-14T11:45:00+00:00 AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://www.newhampshirehealthreport.com/article/905674267-clearmind-medicine-s-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder New Hampshire Health Report en PressRelease 2026-04-14T11:32:00+00:00 Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905670306-sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 New Hampshire Health Report en PressRelease 2026-04-14T11:30:00+00:00 Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/591eb30b-d3e4-428c-9cd6-536215925b01/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905671016-profound-medical-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference New Hampshire Health Report en PressRelease 2026-04-14T11:30:00+00:00 Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://www.newhampshirehealthreport.com/article/905671585-praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor New Hampshire Health Report en PressRelease 2026-04-14T11:30:00+00:00 Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.newhampshirehealthreport.com/article/905672048-anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimer-s-disease New Hampshire Health Report en PressRelease 2026-04-14T11:30:00+00:00 Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.newhampshirehealthreport.com/article/905674084-medicenna-to-present-at-the-2026-bloom-burton-co-healthcare-investor-conference New Hampshire Health Report en PressRelease 2026-04-14T11:30:00+00:00 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg https://www.newhampshirehealthreport.com/article/905674299-avacta-ceo-christina-coughlin-named-as-one-of-in-vivo-s-2026-rising-leaders New Hampshire Health Report en PressRelease 2026-04-14T11:26:11+00:00 Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders https://ml.globenewswire.com/media/63584766-21c6-42e8-944c-7103432b045b/small/avacta-logo-full-color-rgb-oct-2024-jpg.jpg https://www.newhampshirehealthreport.com/article/905669756-adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.newhampshirehealthreport.com/article/905669823-trained-therapeutix-discovery-s-chief-scientific-officer-dr-mulder-honored-with-fellowship-at-the-american-institute-for-medical-and-biological New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE) https://ml.globenewswire.com/media/5f6e0329-ec9c-4ab1-9659-d99b938cce16/small/trained-therapeutix-logo-png.png https://www.newhampshirehealthreport.com/article/905671051-shopify-to-announce-first-quarter-2026-financial-results-may-5-2026 New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Shopify to Announce First-Quarter 2026 Financial Results May 5, 2026 https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.newhampshirehealthreport.com/article/905671069-axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026 New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026 https://ml.globenewswire.com/media/3e4ffe78-2e9a-4972-915e-28c8477c84c1/small/axogen-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905671091-vitalhub-announces-novari-health-referral-central-intake-implementation-in-ontario New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 VitalHub Announces Novari Health Referral Central Intake Implementation in Ontario https://ml.globenewswire.com/media/fae8da93-7d5e-4eb4-9121-d724c8555bce/small/greylogo-png.png https://www.newhampshirehealthreport.com/article/905672083-evolveimmune-therapeutics-to-present-update-on-lead-asset-evolve104-and-new-data-for-evolve-t-cell-engager-platform-at-2026-aacr-annual-meeting New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting https://ml.globenewswire.com/media/43892ec0-88ad-4f85-b32e-7d049f9ed422/small/evolveimmune-png.png https://www.newhampshirehealthreport.com/article/905673210-ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905673892-ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filspari-sparsentan-in-fsgs New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.newhampshirehealthreport.com/article/905674161-tiziana-life-sciences-announces-late-breaking-poster-accepted-for-presentation-at-the-7th-world-parkinson-congress New Hampshire Health Report en PressRelease 2026-04-14T11:00:00+00:00 Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress https://ml.globenewswire.com/media/991c340c-a083-4bcb-ad41-e7eea83f6f97/small/tiziana-logo-png.png https://www.newhampshirehealthreport.com/article/905658105-genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2026 New Hampshire Health Report en PressRelease 2026-04-14T10:22:57+00:00 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905658895-ataibeckley-to-participate-in-upcoming-needham-healthcare-conferences New Hampshire Health Report en PressRelease 2026-04-14T10:00:00+00:00 AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences https://ml.globenewswire.com/media/cea08bf4-0562-45ed-af5c-c9376c48a6eb/small/ataibeckley-horizontal-2color-png.png https://www.newhampshirehealthreport.com/article/905659602-greenwich-lifesciences-provides-update-on-financing-strategy New Hampshire Health Report en PressRelease 2026-04-14T10:00:00+00:00 Greenwich LifeSciences Provides Update on Financing Strategy https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.newhampshirehealthreport.com/article/905647186-nxera-pharma-s-quviviq-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia New Hampshire Health Report en PressRelease 2026-04-14T08:42:59+00:00 Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.newhampshirehealthreport.com/article/905636102-mestag-therapeutics-selected-to-present-targeted-ltbr-agonist-mst-0312-in-late-breaking-session-at-aacr-annual-meeting New Hampshire Health Report en PressRelease 2026-04-14T07:30:00+00:00 Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting https://ml-eu.globenewswire.com/media/d47c1200-a3a8-42b0-b0b9-ffb74568b42c/small/mestag-tx-logo-png.png https://www.newhampshirehealthreport.com/article/905636143-asgard-therapeutics-appoints-professor-dr-wolfram-brugger-as-chief-medical-officer-as-it-advances-transformative-personalized-off-the-shelf New Hampshire Health Report en PressRelease 2026-04-14T07:30:00+00:00 Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development https://ml-eu.globenewswire.com/media/5afbd1fa-9d4b-48d2-8f4f-d262d5a69053/small/asgard-tx-rgb-png.png https://www.newhampshirehealthreport.com/article/905614729-panntherapi-annonce-des-avanc-es-majeures-dans-son-d-veloppement-clinique-et-strat-gique New Hampshire Health Report en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/ https://www.newhampshirehealthreport.com/article/905614774-renaissance-pharma-limited-an-essential-pharma-company-secures-fda-fast-track-designation-and-ind-clearance-for-daretabart-hu1418k322a-in New Hampshire Health Report en PressRelease 2026-04-14T06:00:00+00:00 Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma https://ml-eu.globenewswire.com/media/31276511-f379-4a7a-90b6-af9fc9ac2aa0/small/66795319ca361c8d044a2cc6-essential-pharma-master-logo-png.png https://www.newhampshirehealthreport.com/article/905614817-panntherapi-announces-significant-clinical-development-and-strategic-milestones New Hampshire Health Report en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi Announces Significant Clinical Development and Strategic Milestones https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/logo-png.png https://www.newhampshirehealthreport.com/article/905614845-kuros-biosciences-reports-51-year-over-year-increase-in-sales-in-the-first-three-months-of-2026 New Hampshire Health Report en PressRelease 2026-04-14T05:00:00+00:00 Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 https://ml-eu.globenewswire.com/media/ad3777c9-af1f-4b09-a899-3b3d6b8e962d/small/kuros-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905593433-rapid-nutrition-strengthens-capital-markets-infrastructure-with-appointment-of-bowsprit-partners New Hampshire Health Report en PressRelease 2026-04-14T03:00:00+00:00 Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners https://ml-eu.globenewswire.com/media/f5152816-94d7-4584-a49f-05ae66a44bf0/small/rapid-jpg.jpg https://www.newhampshirehealthreport.com/article/905574910-elite-force-xl-male-enhancement-gummies-claims-evaluated-effective-men-s-formula-for-steel-power-support New Hampshire Health Report en PressRelease 2026-04-14T01:36:27+00:00 Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support https://zingfast.com/wp-content/uploads/2026/04/Elite-Force-XL-Male-Enhancement-Gummies.jpg https://www.newhampshirehealthreport.com/article/905574767-vital-step-glp-1-claims-evaluated-trusted-doctor-prescribed-glp-1-weight-loss-medication-with-no-hidden-fees New Hampshire Health Report en PressRelease 2026-04-14T01:11:21+00:00 Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees https://zingfast.com/wp-content/uploads/2026/04/Vital-Step-GLP-1.jpg https://www.newhampshirehealthreport.com/article/905565700-gloramd-face-lift-serum-claims-evaluated-liquid-anti-aging-wrinkle-serum-solution-for-skin-renewal New Hampshire Health Report en PressRelease 2026-04-14T00:16:02+00:00 GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal https://zingfast.com/wp-content/uploads/2026/04/GloraMD-Face-Lift-Serum.jpg https://www.newhampshirehealthreport.com/article/905557661-biomerica-reports-third-quarter-fiscal-2026-financial-results New Hampshire Health Report en PressRelease 2026-04-13T22:57:27+00:00 Biomerica Reports Third Quarter Fiscal 2026 Financial Results https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://www.newhampshirehealthreport.com/article/905557520-clean-eye-claims-evaluated-the-cleaneye-vision-care-capsules-for-retina-clear-visual-support New Hampshire Health Report en PressRelease 2026-04-13T22:46:54+00:00 Clean Eye Claims Evaluated: The CleanEye Vision Care Capsules for Retina Clear Visual Support https://zingfast.com/wp-content/uploads/2026/04/Clean-Eye.jpg https://www.newhampshirehealthreport.com/article/905549775-ballad-health-s-program-for-assisting-uninsured-patients-earns-national-award-for-its-community-based-approach-to-serving-rural-appalachia New Hampshire Health Report en PressRelease 2026-04-13T22:06:57+00:00 Ballad Health’s program for assisting uninsured patients earns national award for its community-based approach to serving rural Appalachia https://ml.globenewswire.com/media/MWQ0YWI3MDEtY2Q2Mi00NDk0LTk5MDAtNTEwNTEyYzRjY2Y5LTExMzUxNTItMjAyNi0wNC0xMy1lbg==/tiny/Ballad-Health.png https://www.newhampshirehealthreport.com/article/905549588-aim-immunotech-provides-routine-update-on-annual-filings New Hampshire Health Report en PressRelease 2026-04-13T22:00:00+00:00 AIM ImmunoTech Provides Routine Update on Annual Filings https://ml.globenewswire.com/media/8e85b83b-047f-4f99-9c51-1aa232ffe9bb/small/aimlogo-jpg.jpg https://www.newhampshirehealthreport.com/article/905542434-xortx-announces-closing-of-acquisition-of-vectus-kidney-anti-fibrotic-asset New Hampshire Health Report en PressRelease 2026-04-13T21:00:00+00:00 XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset https://ml.globenewswire.com/media/9898c4f8-b373-438a-abfa-709c4372a061/small/xortx-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905542368-spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock New Hampshire Health Report en PressRelease 2026-04-13T20:46:48+00:00 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.newhampshirehealthreport.com/article/905535759-immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillemette-and-dr-anthony-dimarco-to-the-board-and-moves-to-a-smaller New Hampshire Health Report en PressRelease 2026-04-13T20:38:05+00:00 ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors https://ml.globenewswire.com/media/680330c2-368b-4abc-9429-878b0c9fb1a2/small/immucell-jpg.jpg https://www.newhampshirehealthreport.com/article/905535401-bioage-labs-to-present-at-25th-annual-needham-virtual-healthcare-conference New Hampshire Health Report en PressRelease 2026-04-13T20:30:00+00:00 BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.newhampshirehealthreport.com/article/905535572-cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform New Hampshire Health Report en PressRelease 2026-04-13T20:30:00+00:00 Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.newhampshirehealthreport.com/article/905535574-les-donn-es-interm-diaires-de-l-essai-pivot-testant-cema-cel-mettent-en-vidence-la-solidit-de-la-plateforme-car-t-allog-nique-de-cellectis New Hampshire Health Report en PressRelease 2026-04-13T20:30:00+00:00 Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.newhampshirehealthreport.com/article/905535321-sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451 New Hampshire Health Report en PressRelease 2026-04-13T20:05:00+00:00 Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451 https://ml.globenewswire.com/media/2e5b81be-ddf0-4a60-85f1-3f17c242e8c2/small/sana-biotechnology-jpg.jpg https://www.newhampshirehealthreport.com/article/905535567-bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 New Hampshire Health Report en PressRelease 2026-04-13T20:05:00+00:00 BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f5f2b913-06aa-4e1d-9368-55ff15fb3bd6/small/bbot-fullcolor-rgb-png.png https://www.newhampshirehealthreport.com/article/905535390-celldex-to-present-at-upcoming-investor-conference New Hampshire Health Report en PressRelease 2026-04-13T20:01:00+00:00 Celldex to Present at Upcoming Investor Conference https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.newhampshirehealthreport.com/article/905535566-revolution-medicines-inc-announces-proposed-offerings-of-common-stock-and-convertible-senior-notes New Hampshire Health Report en PressRelease 2026-04-13T20:01:00+00:00 Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.newhampshirehealthreport.com/article/905535570-allogene-therapeutics-announces-proposed-public-offering-of-175-million-of-common-stock New Hampshire Health Report en PressRelease 2026-04-13T20:01:00+00:00 Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.newhampshirehealthreport.com/article/905522414-celebrating-national-medical-laboratory-week New Hampshire Health Report en PressRelease 2026-04-13T19:00:00+00:00 Celebrating National Medical Laboratory Week https://ml.globenewswire.com/media/ZWNlYTAwM2UtZDAwNS00MDFjLWJiY2ItZDE4ZTM2YzQyMTM2LTEwOTc1MzMtMjAyNi0wNC0xMy1lbg==/tiny/LifeLabs.png https://www.newhampshirehealthreport.com/article/905516650-seer-confirms-receipt-of-unsolicited-proposal-and-director-candidate-nominations-from-radoff-jec-group New Hampshire Health Report en PressRelease 2026-04-13T17:55:00+00:00 Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.newhampshirehealthreport.com/article/905516710-vital-hemp-gummies-launch-hemp-gummies-australia-nz-or-canada-relieves-anxiety-effective-reduces-pain-relax-stress-with-vital-hemp-2026 New Hampshire Health Report en PressRelease 2026-04-13T17:39:33+00:00 Vital Hemp Gummies | Launch" Hemp Gummies Australia, NZ Or Canada Relieves Anxiety Effective Reduces Pain Relax Stress With Vital Hemp 2026 https://ml-eu.globenewswire.com/Resource/Download/3dd4c2ca-9658-477e-9266-ac54964587d8/image1.png https://www.newhampshirehealthreport.com/article/905511446-dermatology-devices-market-to-reach-25-6-billion-by-2030-driven-by-rising-skin-cancer-incidence-and-aesthetic-demand New Hampshire Health Report en PressRelease 2026-04-13T17:21:11+00:00 Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.newhampshirehealthreport.com/article/905511391-ask4sam-nyc-medical-malpractice-attorneys-silberstein-miklos-p-c-expands-focus-on-representing-patients-across-manhattan-brooklyn-and-queens New Hampshire Health Report en PressRelease 2026-04-13T17:05:00+00:00 ASK4SAM NYC Medical Malpractice Attorneys Silberstein & Miklos, P.C. Expands Focus on Representing Patients Across Manhattan, Brooklyn and Queens https://pressranger.s3.us-west-1.amazonaws.com/3228765/8.png https://www.newhampshirehealthreport.com/article/905506130-centre-for-neuro-skills-named-to-newsweek-s-america-s-greatest-midsize-workplaces-in-health-care-2026 New Hampshire Health Report en PressRelease 2026-04-13T16:17:00+00:00 Centre for Neuro Skills Named to Newsweek’s America’s Greatest Midsize Workplaces in Health Care 2026 https://ml.globenewswire.com/media/3157a281-770d-4ef2-ade7-353df4ceca6b/medium/image2.png https://www.newhampshirehealthreport.com/article/905506215-sienna-for-seniors-foundation-1-million-gift-advances-healthy-aging-research-at-ontario-tech-university New Hampshire Health Report en PressRelease 2026-04-13T16:13:38+00:00 Sienna for Seniors Foundation $1 Million Gift Advances Healthy Aging Research at Ontario Tech University https://ml.globenewswire.com/media/9765702b-cb47-4b36-8255-d86b22ef3df3/medium/ontario-tech-university-and-sienna-senior-living-celebrate-t.jpg https://www.newhampshirehealthreport.com/article/905506159-radical-catheter-technologies-announces-u-s-fda-510-k-clearance-for-its-6f-neurovascular-catheter-broadening-access-across-a-wide-range-of New Hampshire Health Report en PressRelease 2026-04-13T16:05:00+00:00 Radical™ Catheter Technologies Announces U.S. FDA 510(k) Clearance for its 6F Neurovascular Catheter -- Broadening Access Across a Wide Range of Applications https://ml.globenewswire.com/media/5177f2ec-c584-4237-9659-cc7c70377b47/small/radical-catheter-stacked-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905501361-american-kidney-fund-announces-2026-class-of-corporate-members-supporting-work-to-fight-kidney-disease New Hampshire Health Report en PressRelease 2026-04-13T15:37:08+00:00 American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease https://ml.globenewswire.com/media/MDkzZjJmMDYtN2I0OC00MTYwLWFlNTItZTBlNDJlMDBmNDk0LTExMDkwNTItMjAyNi0wNC0xMy1lbg==/tiny/American-Kidney-Fund.png https://www.newhampshirehealthreport.com/article/905483211-biomx-accelerates-defense-technology-buildout-with-dfsl-acquisition New Hampshire Health Report en PressRelease 2026-04-13T13:20:00+00:00 BiomX Accelerates Defense Technology Buildout with DFSL Acquisition https://ml.globenewswire.com/media/OGZiY2U5N2EtNDEzNS00MjcyLWJiZjUtODViOTA2ZTkxZjdhLTEzMjE4NzEtMjAyNi0wNC0xMy1lbg==/tiny/BiomX.png https://www.newhampshirehealthreport.com/article/905482689-polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026 New Hampshire Health Report en PressRelease 2026-04-13T13:15:00+00:00 PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 https://ml.globenewswire.com/media/6016c990-606d-49e6-a7a8-4d88bace509a/medium/figure-1.png https://www.newhampshirehealthreport.com/article/905483265-safespace-global-corporation-announces-operational-expansion-to-support-commercial-deployment-of-its-ai-safety-platform-and-growing-revenue-activities New Hampshire Health Report en PressRelease 2026-04-13T13:15:00+00:00 SafeSpace Global Corporation Announces Operational Expansion to Support Commercial Deployment of its AI-safety platform and Growing Revenue Activities https://ml.globenewswire.com/media/e95639ca-a47d-4c90-a44e-cf8a03b6a6d2/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905482794-switchback-medical-signs-lease-for-18-000-square-foot-facility-in-costa-rica-s-coyol-free-trade-zone New Hampshire Health Report en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.newhampshirehealthreport.com/article/905482824-switchback-medical-firma-contrato-de-arrendamiento-para-una-instalaci-n-de-18-000-pies-cuadrados-en-la-zona-franca-coyol-de-costa-rica New Hampshire Health Report en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical firma contrato de arrendamiento para una instalación de 18,000 pies cuadrados en la Zona Franca Coyol de Costa Rica https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.newhampshirehealthreport.com/article/905482882-neomorph-announces-closing-of-100-million-series-b-financing New Hampshire Health Report en PressRelease 2026-04-13T13:00:00+00:00 Neomorph Announces Closing of $100 Million Series B Financing https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905482931-senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026 New Hampshire Health Report en PressRelease 2026-04-13T13:00:00+00:00 Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 https://ml.globenewswire.com/media/19732ef2-d354-4281-9dc5-6000f190dd83/small/sentibiologo-jpg.jpg https://www.newhampshirehealthreport.com/article/905478607-free-oral-cancer-screenings-in-honor-of-oral-head-and-neck-cancer-awareness-month New Hampshire Health Report en PressRelease 2026-04-13T12:45:00+00:00 Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month https://ml.globenewswire.com/media/9472c27c-8b6d-4c87-95fd-31f1f0140263/small/usosm-logo-png.png https://www.newhampshirehealthreport.com/article/905478665-xealth-to-facilitate-critical-discussion-among-health-system-executives-on-how-to-maximize-digital-health-value-at-becker-s-annual-meeting New Hampshire Health Report en PressRelease 2026-04-13T12:33:00+00:00 Xealth to Facilitate Critical Discussion Among Health System Executives on How to Maximize Digital Health Value at Becker’s Annual Meeting https://ml.globenewswire.com/media/33a9b40b-a04e-464b-b15f-f7180c2168ce/small/picture1-png.png https://www.newhampshirehealthreport.com/article/905478602-optum-united-healthcare-united-behavioral-health-expands-neurostar-tms-coverage-to-include-psychiatric-mental-health-nurse-practitioners New Hampshire Health Report en PressRelease 2026-04-13T12:32:00+00:00 Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.newhampshirehealthreport.com/article/905478464-alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer New Hampshire Health Report en PressRelease 2026-04-13T12:30:00+00:00 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://www.newhampshirehealthreport.com/article/905478584-oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury New Hampshire Health Report en PressRelease 2026-04-13T12:30:00+00:00 Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905478638-microbot-medical-commences-full-market-release-fmr-of-the-liberty-endovascular-robotic-system-in-the-u-s-at-the-society-of-interventional New Hampshire Health Report en PressRelease 2026-04-13T12:30:00+00:00 Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.newhampshirehealthreport.com/article/905478648-heartflow-files-patent-infringement-lawsuit-against-cleerly New Hampshire Health Report en PressRelease 2026-04-13T12:30:00+00:00 Heartflow Files Patent Infringement Lawsuit Against Cleerly https://ml.globenewswire.com/media/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15/small/25-1113-cmyk-hf-logo-positive-png.png https://www.newhampshirehealthreport.com/article/905478660-inspira-begins-ame-technology-implementation-process-with-one-of-the-world-s-10-largest-u-s-based-companies New Hampshire Health Report en PressRelease 2026-04-13T12:16:00+00:00 Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.newhampshirehealthreport.com/article/905478477-chemed-corporation-announces-a-five-year-450-million-amended-and-restated-credit-agreement New Hampshire Health Report en PressRelease 2026-04-13T12:15:00+00:00 Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.newhampshirehealthreport.com/article/905474851-nanox-signs-distribution-agreement-with-digital-x-ray-imaging-to-expand-nanox-arc-adoption-in-arkansas New Hampshire Health Report en PressRelease 2026-04-13T12:10:00+00:00 Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://www.newhampshirehealthreport.com/article/905474794-veld-pharmaceuticals-gmbh-announces-collaboration-with-chiesi-farmaceutici-s-p-a-to-expand-access-to-rare-disease-therapies-across-africa New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa https://ml-eu.globenewswire.com/media/047cc83e-f777-4658-9d34-e499423ec123/small/logo-veld-png.png https://www.newhampshirehealthreport.com/article/905474801-impact-biotech-presents-preliminary-data-from-phase-1-study-of-padeliporfin-vtp-in-la-pdac-at-sir-2026-and-provides-strategic-business-update New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update https://ml-eu.globenewswire.com/media/68762066-1fff-4065-af45-d18da25273cd/small/impact-biotech-logo-final-resized-jpg.jpg https://www.newhampshirehealthreport.com/article/905474927-geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chief-legal-officer-and-corporate-secretary New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905474962-pacira-presents-real-world-data-on-exparel-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://www.newhampshirehealthreport.com/article/905474978-brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905474988-septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.newhampshirehealthreport.com/article/905475004-favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905475007-stryker-signs-definitive-agreement-to-acquire-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio https://ml.globenewswire.com/media/c24fe8bd-9db6-4f42-8a52-06a4e1b673b5/small/stryker-logo2015-jpg.jpg https://www.newhampshirehealthreport.com/article/905475009-praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026 New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.newhampshirehealthreport.com/article/905475038-cvrx-reports-preliminary-first-quarter-2026-financial-results New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 CVRx Reports Preliminary First Quarter 2026 Financial Results https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.newhampshirehealthreport.com/article/905475045-daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.newhampshirehealthreport.com/article/905475055-eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.newhampshirehealthreport.com/article/905475064-akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-akb-9090 New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.newhampshirehealthreport.com/article/905475065-catheter-precision-announces-accepted-publication-in-leading-european-medical-journal New Hampshire Health Report en PressRelease 2026-04-13T12:00:00+00:00 Catheter Precision Announces Accepted Publication in Leading European Medical Journal https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.newhampshirehealthreport.com/article/905474987-nervgen-pharma-to-participate-in-the-h-c-wainwright-hcw-home-series-and-the-2026-bloom-burton-co-healthcare-investor-conference New Hampshire Health Report en PressRelease 2026-04-13T11:45:00+00:00 NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.newhampshirehealthreport.com/article/905475034-with-brain-scan-volume-momentum-accelerating-firefly-makes-history-by-building-the-world-s-first-known-200-000-standardized-eeg-erp-depository New Hampshire Health Report en PressRelease 2026-04-13T11:45:00+00:00 With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository https://ml.globenewswire.com/media/cd317e6a-730f-4537-a096-9b724abb964e/small/firefly-png.png https://www.newhampshirehealthreport.com/article/905470717-allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel New Hampshire Health Report en PressRelease 2026-04-13T11:30:00+00:00 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.newhampshirehealthreport.com/article/905470753-vireo-growth-announces-california-retail-joint-venture-with-glass-house-brands New Hampshire Health Report en PressRelease 2026-04-13T11:30:00+00:00 Vireo Growth Announces California Retail Joint Venture with Glass House Brands https://ml.globenewswire.com/media/d01c0dca-8260-48c8-8ead-e09111cf57b5/small/vireo-horizontalllogolockup-01-png.png https://www.newhampshirehealthreport.com/article/905470768-newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement New Hampshire Health Report en PressRelease 2026-04-13T11:30:00+00:00 Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905470778-northstrive-biosciences-announces-u-s-arrival-of-el-32-working-cell-bank-and-initiation-of-manufacturing-optimization-for-dual-myostatin-assets New Hampshire Health Report en PressRelease 2026-04-13T11:30:00+00:00 NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences https://ml.globenewswire.com/media/b1dabc1a-ea7b-49d8-a9cd-406fd48dd65b/small/logo-color-1-jpg.jpg https://www.newhampshirehealthreport.com/article/905470800-palvella-therapeutics-appoints-john-d-doux-m-d-m-b-a-dermatologist-and-recognized-leader-in-rare-skin-diseases-to-board-of-directors New Hampshire Health Report en PressRelease 2026-04-13T11:30:00+00:00 Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.newhampshirehealthreport.com/article/905470793-gelatide-drops-investigated-2026-report-what-consumers-should-verify-before-buying New Hampshire Health Report en PressRelease 2026-04-13T11:23:50+00:00 Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying https://ml.globenewswire.com/Resource/Download/984a2986-fdd3-4fe6-80f2-312f9d1cbc94/image2.png https://www.newhampshirehealthreport.com/article/905467090-from-milestone-to-momentum-kraig-biocraft-leadership-travels-to-south-east-asia-following-record-setting-1-3-metric-ton-recombinant-spider-silk New Hampshire Health Report en PressRelease 2026-04-13T11:05:00+00:00 From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905466754-oxb-launches-fast-track-offering-for-aav-and-lentiviral-vector-platforms-accelerating-viral-vector-development-and-manufacture New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture https://ml-eu.globenewswire.com/media/3e905c0a-b28c-4981-ac57-745647779ad9/small/oxb-new-logo-png.png https://www.newhampshirehealthreport.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://www.newhampshirehealthreport.com/article/905466931-soleo-health-opens-new-ambulatory-infusion-center-in-louisville-kentucky New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 Soleo Health Opens New Ambulatory Infusion Center in Louisville, Kentucky https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.newhampshirehealthreport.com/article/905466947-nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-company-s-first-chief-commercial-officer New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.newhampshirehealthreport.com/article/905466972-kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.newhampshirehealthreport.com/article/905466973-spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.newhampshirehealthreport.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905467081-imagenebio-announces-30-million-private-placement New Hampshire Health Report en PressRelease 2026-04-13T11:00:00+00:00 ImageneBio Announces $30 Million Private Placement https://ml.globenewswire.com/media/ccccc30d-a51c-48d7-9aec-6b542240c611/small/imagene-logo-green-jpg.jpg https://www.newhampshirehealthreport.com/article/905466794-ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules New Hampshire Health Report en PressRelease 2026-04-13T10:50:00+00:00 ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.newhampshirehealthreport.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency New Hampshire Health Report en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://www.newhampshirehealthreport.com/article/905463063-regeneron-and-telix-announce-strategic-radiopharma-collaboration New Hampshire Health Report en PressRelease 2026-04-13T10:30:00+00:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration New Hampshire Health Report en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.newhampshirehealthreport.com/article/905459654-prosomnus-receives-fda-class-ii-clearance-for-rpmo2-osa-device New Hampshire Health Report en PressRelease 2026-04-13T10:00:00+00:00 ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device https://ml.globenewswire.com/media/333d9b0e-92b8-4e8b-ab32-6689f4113578/medium/prosomnus-rpmo2-osa-device-system.jpg https://www.newhampshirehealthreport.com/article/905451931-smart-minimalism-supreme-efficiency-cuktech-15-charging-station-makes-its-debut-in-malaysia New Hampshire Health Report en PressRelease 2026-04-13T08:40:54+00:00 Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.newhampshirehealthreport.com/article/905452017-berikut-adalah-terjemahan-siaran-akhbar-tersebut-ke-dalam-bahasa-melayu-minimalisme-pintar-kecekapan-ulung-stesen-pengecasan-cuktech-15-membuat New Hampshire Health Report en PressRelease 2026-04-13T08:40:54+00:00 Berikut adalah terjemahan siaran akhbar tersebut ke dalam Bahasa Melayu: Minimalisme Pintar, Kecekapan Ulung: Stesen Pengecasan CUKTECH 15 Membuat Kemunculan Sulung di Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.newhampshirehealthreport.com/article/905445010-epitopea-strengthens-scientific-advisory-board-with-appointment-of-leading-authority-in-cancer-lisa-butterfield New Hampshire Health Report en PressRelease 2026-04-13T08:00:00+00:00 Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.newhampshirehealthreport.com/article/905445013-epitopea-renforce-son-comit-consultatif-scientifique-avec-la-nomination-de-lisa-butterfield-figure-de-renom-dans-le-domaine-du-cancer New Hampshire Health Report en PressRelease 2026-04-13T08:00:00+00:00 Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.newhampshirehealthreport.com/article/905445007-boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows New Hampshire Health Report en PressRelease 2026-04-13T07:51:00+00:00 Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.newhampshirehealthreport.com/article/905445021-rising-uk-dental-costs-and-nhs-access-crisis-drive-record-demand-for-treatment-in-t-rkiye-dentspa-leads-the-response New Hampshire Health Report en PressRelease 2026-04-13T07:30:00+00:00 Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response https://ml-eu.globenewswire.com/media/53fb3ee2-7271-4c5f-b8b5-f4e6db89cc89/small/dentspa-logo-blue-png.png https://www.newhampshirehealthreport.com/article/905432311-transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer New Hampshire Health Report en PressRelease 2026-04-13T06:00:00+00:00 Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer https://ml-eu.globenewswire.com/media/a1e966ec-4255-431c-b28a-c40c9e1f8733/small/transgene-logo-rvb2026-png.png https://www.newhampshirehealthreport.com/article/905432314-transgene-annonce-la-fin-de-la-randomisation-des-patients-de-la-partie-phase-2-de-l-essai-clinique-valuant-tg4050-dans-le-traitement-adjuvant-des New Hampshire Health Report en PressRelease 2026-04-13T06:00:00+00:00 Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou https://ml-eu.globenewswire.com/media/2a0cee23-0b14-48ff-8db2-e5e966dd7bb5/small/transgene-logo-rvb2026-png.png https://www.newhampshirehealthreport.com/article/905432318-synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study-supporting-emactuzumab-as-a-differentiated-next-generation New Hampshire Health Report en PressRelease 2026-04-13T06:00:00+00:00 SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) https://ml.globenewswire.com/media/35d87dbe-62e3-4299-9eba-3ccdbea5d85e/small/synox-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous New Hampshire Health Report en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez New Hampshire Health Report en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905424246-data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with-ethionamide-alpe New Hampshire Health Report en PressRelease 2026-04-13T05:00:00+00:00 Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://www.newhampshirehealthreport.com/article/905424249-dupixent-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu New Hampshire Health Report en PressRelease 2026-04-13T05:00:00+00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.newhampshirehealthreport.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia New Hampshire Health Report en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.newhampshirehealthreport.com/article/905363129-scrap-the-ban-keep-the-controls-caphra-s-message-to-bangladesh New Hampshire Health Report en PressRelease 2026-04-12T20:56:25+00:00 Scrap the Ban, Keep the Controls: CAPHRA's Message to Bangladesh https://ml.globenewswire.com/media/6dc95f2d-65fb-409f-aed4-9ebe55554004/small/picture1-png.png